Clinical Trial Update: An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection [Phase 2, Phase 3]

View source ↗

Summary

Open-label, nonrandomized study evaluating safety and immunogenicity of Raxibacumab with reinjection in inhalation anthrax; completed with results posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inhalation Anthrax

Drugs mentioned

• Raxibacumab (raxibacumab)

Snippet

Sponsor: Human Genome Sciences Inc. | Conditions: Therapeutic Treatment of Inhalation Anthrax | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-06-25